Want to see IT:EUK full AI Analyst Report?
Top Page
Eukedos S.p.A.
(EUK)
Select Model
Select Model
Rating:44Neutral
Price Target:
€0.49
▼(-31.94% Downside)
Action:Reiterated
Date:06/09/26
The score is primarily constrained by financial risk: very high leverage and a shift to net losses in 2024–2025, despite steady operating margins and positive operating cash flow. Technically, the stock is below major moving averages, signaling a weaker trend, while valuation is difficult to support with a negative P/E and no dividend yield data.
Positive Factors
Resilient operating margins
Eukedos has maintained steady operating margins (EBIT ~9–11%, EBITDA ~20–25%) across 2021–2025. Stable underlying operating profitability supports ability to fund operations and services, providing a durable earnings base even if net results fluctuate.
Negative Factors
Very high leverage
Debt-to-equity near 3.3–4.4x and rising total debt materially in 2025 sharply constrain financial flexibility. High leverage increases refinancing and interest-rate sensitivity, reducing resilience to revenue shocks and limiting capacity for strategic investment over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Resilient operating margins
Eukedos has maintained steady operating margins (EBIT ~9–11%, EBITDA ~20–25%) across 2021–2025. Stable underlying operating profitability supports ability to fund operations and services, providing a durable earnings base even if net results fluctuate.
Read all positive factors
Eukedos S.p.A. (EUK) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€11.48M
Dividend YieldN/A
Average Volume (3M)4.68K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth2.31%
EPS Growth-43.04%
CountryIT
Employees613
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,741,629
10 Day Avg. Volume3,064
30 Day Avg. Volume4,678
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.55
Price to Sales (P/S)0.31
P/FCF Ratio36.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eukedos S.p.A. Business Overview & Revenue Model
Company Description
EuKedos S.p.A. operates in Italy, offering a range of managed and long-term care provisions. The company specializes in delivering residential social support for older adults, catering to both independent individuals and those needing extensive as...
How the Company Makes Money
null...
Eukedos S.p.A. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
29
Negative
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.64M | 51.69M | 49.45M | 47.04M | 45.18M |
| Gross Profit | 12.09M | 48.96M | 13.73M | 32.03M | 32.99M |
| EBITDA | 10.26M | 12.27M | 12.41M | 10.87M | 10.72M |
| Net Income | -749.00K | -524.00K | 556.00K | 443.00K | 570.00K |
Balance Sheet | |||||
| Total Assets | 180.33M | 179.34M | 149.10M | 153.38M | 150.08M |
| Cash, Cash Equivalents and Short-Term Investments | 416.00K | 3.91M | 2.33M | 3.62M | 7.39M |
| Total Debt | 128.29M | 99.02M | 105.83M | 111.45M | 108.95M |
| Total Liabilities | 151.23M | 149.50M | 119.19M | 123.99M | 121.26M |
| Stockholders Equity | 29.10M | 29.84M | 29.91M | 29.39M | 28.82M |
Cash Flow | |||||
| Free Cash Flow | 436.00K | -13.14M | 3.59M | 1.03M | 5.31M |
| Operating Cash Flow | 6.24M | 9.94M | 10.08M | 5.18M | 5.61M |
| Investing Cash Flow | -5.86M | -58.49M | -8.92M | -4.15M | -306.00K |
| Financing Cash Flow | -3.87M | 50.13M | -2.45M | -4.79M | -562.00K |
Eukedos S.p.A. Technical Analysis
Negative
0.72
Price Trends
0.61
Negative
0.61
Negative
0.66
Negative
Market Momentum
-0.03
Positive
22.79
Positive
11.76
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:EUK, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.61, and above the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 22.79 is Positive, neither overbought nor oversold. The STOCH value of 11.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:EUK.
Eukedos S.p.A. Peers Comparison
UnderperformOutperform
Sector (51)
IT:EUK
Eukedos S.p.A.
0.51
-0.28
-35.26%
IT:ARBS
Arterra Bioscience SpA
3.19
0.79
33.08%
IT:COSMO
Farmacosmo S.P.A.
0.49
-0.03
-6.18%
IT:SVS
Svas Biosana S.p.A.
8.32
0.36
4.52%
IT:IMD
I.M.D. International Medical Devices S.P.A.
1.30
-0.02
-1.89%
IT:PMED
Piu Medical S.P.A.
5.90
0.10
1.64%
Eukedos S.p.A. Corporate Events
Eukedos Revises Board Line-Up and Committees After Co-Option Change
Jul 29, 2026
Eukedos S.p.A. has announced that Lenthona, previously designated by co-option as an independent, non-executive director, has declined the appointment due to concerns over interpretative uncertainties pending new implementing regulations under the...
Eukedos Names New Officer in Charge of Accounting Documents
Jul 3, 2026
Eukedos S.p.A., an Italian healthcare and social care services provider focused on elderly and assisted living facilities, operates under the direction and coordination of La Villa S.p.A. and manages a portfolio of care-focused assets across Italy...
Eukedos Reshapes Portfolio and Financing to Back New Elderly Residences
Jun 23, 2026
Eukedos S.p.A. has sold its 40.24% stake in Poggio Imperiale Srl to related party La Veranella Srl for €2.6 million, consolidating ownership of the company under an entity that already held the majority. The agreed price, previously disclose...
Eukedos Publishes Minutes of 29 April 2026 Shareholders’ Meeting
Jun 18, 2026
Eukedos S.p.A. has made available to the public the minutes of its Ordinary Shareholders’ Meeting held on 29 April 2026, in line with regulatory and governance best practices. The documents can be consulted at the company’s registered ...
Eukedos Sells Poggio Imperiale Stake and Refreshes Board Composition
Jun 10, 2026
Eukedos has approved the sale of its 40.24% stake in Poggio Imperiale S.r.l. to related party La Veranella S.r.l., a company fully owned by La Villa S.p.A., which already controls Poggio Imperiale. The transaction, priced at 2.6 million euro and y...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.